Uncategorized
The U.S. infant mortality rate fell to an all-time low, though it still trails other similar nations
NEW YORK — Infant mortality in the U.S. dropped to a new all-time low in 2025, according to preliminary government data.
There were slightly fewer than 5.4 infant deaths per 1,000 live births in 2025, according to the Centers for Disease Control and Prevention.
NEW YORK — Infant mortality in the U.S. dropped to a new all-time low in 2025, according to preliminary government data.
There were slightly fewer than 5.4 infant deaths per 1,000 live births in 2025, according to the Centers for Disease Control and Prevention.
Uncategorized
STAT+: Pharmalittle: We’re reading about hackers extorting Novo, an FDA about-face, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a needed cup of stimulation. Our choice today is maple bourbon. A shot of salvation, if you will. Meanwhile, here is the latest menu of tidbits to help you on your way. We hope you conquer the world and have a wonderful day. And as always, please do stay in touch. …
A cyber extortion group claimed to have stolen more than a terabyte of data from Novo Nordisk and said it is exploring selling parts of the data after unsuccessfully demanding $25 million from the company, Reuters reports. FulcrumSec, a cyber extortion group that emerged in October 2025, said in a long message posted to its website that it spent more than two months in Novo Nordisk’s networks stealing data. It said that data included company source code, proprietary information on released and unreleased drugs, trial data, employee, doctor, and patient data, information related to company processing facilities, and internal AI model information.
The U.S. Food and Drug Administration reversed its opposition to a closely watched experimental treatment for Huntington’s disease, clearing a path for UniQure to file for marketing approval, STAT writes. The decision comes after a recent meeting with FDA officials during which the agency agreed that a three-year analysis of an early-stage study that showed a benefit for patients with Huntington’s was “acceptable” to support a marketing application. These are the same data that former FDA officials, most notably Commissioner Marty Makary and Vinay Prasad, the agency’s top regulator of cell and gene therapies, previously concluded were insufficient to support a marketing application.
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a needed cup of stimulation. Our choice today is maple bourbon. A shot of salvation, if you will. Meanwhile, here is the latest menu of tidbits to help you on your way. We hope you conquer the world and have a wonderful day. And as always, please do stay in touch. …
A cyber extortion group claimed to have stolen more than a terabyte of data from Novo Nordisk and said it is exploring selling parts of the data after unsuccessfully demanding $25 million from the company, Reuters reports. FulcrumSec, a cyber extortion group that emerged in October 2025, said in a long message posted to its website that it spent more than two months in Novo Nordisk’s networks stealing data. It said that data included company source code, proprietary information on released and unreleased drugs, trial data, employee, doctor, and patient data, information related to company processing facilities, and internal AI model information.
The U.S. Food and Drug Administration reversed its opposition to a closely watched experimental treatment for Huntington’s disease, clearing a path for UniQure to file for marketing approval, STAT writes. The decision comes after a recent meeting with FDA officials during which the agency agreed that a three-year analysis of an early-stage study that showed a benefit for patients with Huntington’s was “acceptable” to support a marketing application. These are the same data that former FDA officials, most notably Commissioner Marty Makary and Vinay Prasad, the agency’s top regulator of cell and gene therapies, previously concluded were insufficient to support a marketing application.
Be Biopharma’s terminated trial is the latest setback in the hemophilia space, where companies like Pfizer and BioMarin have opted to pull their respective products from the market after weak traction.
Uncategorized
STAT+: Is Abridge’s ‘patient centered’ claim a bridge too far?
You’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine. Sign up to get it delivered in your inbox every Wednesday.
I cried reading about people’s shared moments with strangers at the bottom of last week’s edition of “We’re Here,” the community newsletter from Hank and John Green.
My colleague Eric Boodman’s stories usually make me cry as well, but his recent article about babies being born with congenital syphilis, which is usually totally preventable with penicillin from Pfizer, made me want to tear my hair out.
You’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine. Sign up to get it delivered in your inbox every Wednesday.
I cried reading about people’s shared moments with strangers at the bottom of last week’s edition of “We’re Here,” the community newsletter from Hank and John Green.
My colleague Eric Boodman’s stories usually make me cry as well, but his recent article about babies being born with congenital syphilis, which is usually totally preventable with penicillin from Pfizer, made me want to tear my hair out.
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
STAT+: Pharmalittle: We’re reading about hackers extorting Novo, an FDA about-face, and more
Be Bio bins hemophilia B cell therapy trial—the biotech’s lead program
STAT+: Is Abridge’s ‘patient centered’ claim a bridge too far?
Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short
Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact
Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Uncategorized9 years ago
According to Dior Couture, this taboo fashion accessory is back
-
Endpoints News3 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized9 years ago
Phillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years ago
Uber and Lyft are finally available in all of New York State
-
Uncategorized9 years ago
Steph Curry finally got the contract he deserves from the Warriors
-
Contributors9 years ago
The final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized3 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion